MedPath

A study of the non-invasive evaluation of non-alcoholic fatty liver disease and liver fibrosis in patients with type 2 diabetes mellitus using Fibrosca

Not Applicable
Not yet recruiting
Conditions
Type 2 diabetes mellitus
Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Liver fibrosis
Metabolic and Endocrine - Diabetes
Registration Number
ACTRN12609000221257
Lead Sponsor
The Alfred Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not yet recruiting
Sex
All
Target Recruitment
200
Inclusion Criteria

Type 2 diabetes

Exclusion Criteria

Body Mass Index(BMI)>35
Bleeding disorder
Creatinine>200
International Normalised Ratio(INR)>1.5
Platelets<75
Anti-platelet agent use
Major medical co-morbidities

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath